Brought to you by 
Avidia closes $28.5mm Series B round
26 Oct 2012
Executive Summary
Avidia Inc. (protein therapeutics) raised $28.5mm through the sale of Series B preferred shares. Morgenthaler Ventures led the round and was joined by other new investors TPG Ventures, MedImmune Ventures, and Amgen Ventures, and returning backers Alloy Ventures, Maxygen (which created Avida in 2003 as a spin-off), Avidia scientific founder Willem Stemmer, and other individuals.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com